Latest From Relay Therapeutics
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.
2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more...
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Relay Therapeutics
- Senior Management
Sanjiv K Patel, MD, Pres. & CEO
Don Bergstrom, MD, PhD, EVP, Head, R&D
Tom Catinazzo, VP, Fin.
- Contact Info
Phone: (617) 370-8837
215 First St.
Cambridge, MA 02142
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.